Literature DB >> 19834028

Role of IL-6 in angiotensin II-induced retinal vascular inflammation.

Modesto Rojas1, Wenbo Zhang, Dexter L Lee, Maritza J Romero, Doan T Nguyen, Mohamed Al-Shabrawey, Nai-Tse Tsai, Gregory I Liou, Michael W Brands, Robert W Caldwell, Ruth B Caldwell.   

Abstract

PURPOSE: The production of proinflammatory cytokines has been shown to play a critical role in a variety of retinal vascular diseases. Angiotensin II and VEGF have been implicated in the initiation of vascular inflammation and retinal vascular disease. However, detailed mechanisms of this process and interactions between inflammatory agonists and angiotensin II in promoting retinopathy are poorly understood. The present study was an investigation of the role of interleukin (IL)-6 in angiotensin II-induced retinopathy.
METHODS: Rats and IL-6-deficient and wild-type mice were treated with angiotensin II or IL-6, and their retinas were analyzed for leukocyte adhesion or for the expression and localization of VEGF or IL-6. Leukocyte adhesion was assayed by concanavalin A labeling. Vascular density was determined by morphometric analysis. NADPH oxidase activity was assayed by dihydroethidium imaging of superoxide.
RESULTS: Intravitreal injection of angiotensin II caused increases in IL-6 mRNA and protein and in leukocyte adhesion to the retinal vessels. IL-6 protein was localized to CD11b-positive microglia and macrophage-like cells. Angiotensin II treatment stimulated increases in retinal levels of VEGF expression and NADPH oxidase activity, which were associated with increased surface area and remodeling of the retinal vessels. These effects were blocked by knocking out IL-6. Intravitreal IL-6 directly induced leukocyte adhesion in both wild-type and IL-6-deficient mice.
CONCLUSIONS: The results indicate that IL-6 expression is essential for angiotensin II-induced increases in retinal VEGF expression, leukostasis, and vascular remodeling. The data suggest a critical role for IL-6 in mediating angiotensin II-induced retinal vascular inflammation and remodeling.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19834028      PMCID: PMC2868419          DOI: 10.1167/iovs.09-3375

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  37 in total

1.  Relationship between vascular endothelial growth factor and interleukin-6 in diabetic retinopathy.

Authors:  H Funatsu; H Yamashita; E Shimizu; R Kojima; S Hori
Journal:  Retina       Date:  2001       Impact factor: 4.256

2.  Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema.

Authors:  Hideharu Funatsu; Hidetoshi Yamashita; Hidetaka Noma; Tatsuya Mimura; Tetsuji Yamashita; Sadao Hori
Journal:  Am J Ophthalmol       Date:  2002-01       Impact factor: 5.258

3.  Hyperoxia/normoxia-driven retinal angiogenesis in mice: a role for angiotensin II.

Authors:  M Lonchampt; L Pennel; J Duhault
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-02       Impact factor: 4.799

4.  Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway.

Authors:  Lin-Hung Wei; Min-Liang Kuo; Chi-An Chen; Chia-Hung Chou; Kuo-Bau Lai; Chien-Nan Lee; Chang-Yao Hsieh
Journal:  Oncogene       Date:  2003-03-13       Impact factor: 9.867

5.  Endothelial cell hypertrophy induced by vascular endothelial growth factor in the retina: new insights into the pathogenesis of capillary nonperfusion.

Authors:  P Hofman; B C van Blijswijk; P J Gaillard; G F Vrensen; R O Schlingemann
Journal:  Arch Ophthalmol       Date:  2001-06

6.  Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells.

Authors:  N Ferrara; W J Henzel
Journal:  Biochem Biophys Res Commun       Date:  1989-06-15       Impact factor: 3.575

7.  Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate.

Authors:  Michael J Tolentino; D Scott McLeod; Makoto Taomoto; Tsuyoshi Otsuji; Anthony P Adamis; Gerard A Lutty
Journal:  Am J Ophthalmol       Date:  2002-03       Impact factor: 5.258

Review 8.  Vascular inflammation and the renin-angiotensin system.

Authors:  Allan R Brasier; Adrian Recinos; Mohsen S Eledrisi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-08-01       Impact factor: 8.311

9.  Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol.

Authors:  J Stolk; T J Hiltermann; J H Dijkman; A J Verhoeven
Journal:  Am J Respir Cell Mol Biol       Date:  1994-07       Impact factor: 6.914

10.  Induction of interleukin 6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor-IL-6.

Authors:  S F Yan; I Tritto; D Pinsky; H Liao; J Huang; G Fuller; J Brett; L May; D Stern
Journal:  J Biol Chem       Date:  1995-05-12       Impact factor: 5.157

View more
  36 in total

1.  Bone Marrow-Derived Cells Restore Functional Integrity of the Gut Epithelial and Vascular Barriers in a Model of Diabetes and ACE2 Deficiency.

Authors:  Yaqian Duan; Ram Prasad; Dongni Feng; Eleni Beli; Sergio Li Calzi; Ana Leda F Longhini; Regina Lamendella; Jason L Floyd; Mariana Dupont; Sunil K Noothi; Gopalkrishna Sreejit; Baskaran Athmanathan; Justin Wright; Amanda R Jensen; Gavin Y Oudit; Troy A Markel; Prabhakara R Nagareddy; Alexander G Obukhov; Maria B Grant
Journal:  Circ Res       Date:  2019-10-15       Impact factor: 17.367

2.  Mechanisms underlying the cerebral microvascular responses to angiotensin II-induced hypertension.

Authors:  Shantel A Vital; Satoshi Terao; Mutsumi Nagai; D Neil Granger
Journal:  Microcirculation       Date:  2010-11       Impact factor: 2.628

3.  Neuroprotection from retinal ischemia/reperfusion injury by NOX2 NADPH oxidase deletion.

Authors:  Harumasa Yokota; Subhadra P Narayanan; Wenbo Zhang; Hua Liu; Modesto Rojas; Zhimin Xu; Tahira Lemtalsi; Taiji Nagaoka; Akitoshi Yoshida; Steven E Brooks; Robert W Caldwell; Ruth B Caldwell
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-10-11       Impact factor: 4.799

4.  Role of T lymphocytes in angiotensin II-mediated microvascular thrombosis.

Authors:  Elena Y Senchenkova; Janice Russell; Elvira Kurmaeva; Dmitry Ostanin; D Neil Granger
Journal:  Hypertension       Date:  2011-09-12       Impact factor: 10.190

5.  Antibody treatment promotes compensation for human cytomegalovirus-induced pathogenesis and a hypoxia-like condition in placentas with congenital infection.

Authors:  Ekaterina Maidji; Giovanni Nigro; Takako Tabata; Susan McDonagh; Naoki Nozawa; Stephen Shiboski; Stefania Muci; Maurizio M Anceschi; Natali Aziz; Stuart P Adler; Lenore Pereira
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

6.  Adeno-Associated Virus Overexpression of Angiotensin-Converting Enzyme-2 Reverses Diabetic Retinopathy in Type 1 Diabetes in Mice.

Authors:  James M Dominguez; Ping Hu; Sergio Caballero; Leni Moldovan; Amrisha Verma; Gavin Y Oudit; Qiuhong Li; Maria B Grant
Journal:  Am J Pathol       Date:  2016-05-10       Impact factor: 4.307

Review 7.  Anti-inflammatory therapy for diabetic retinopathy.

Authors:  Wenbo Zhang; Hua Liu; Modesto Rojas; Robert W Caldwell; Ruth B Caldwell
Journal:  Immunotherapy       Date:  2011-05       Impact factor: 4.196

Review 8.  Müller cells and diabetic retinopathy.

Authors:  Brandon A Coughlin; Derrick J Feenstra; Susanne Mohr
Journal:  Vision Res       Date:  2017-09-05       Impact factor: 1.886

9.  Ocular cytomegalovirus latency exacerbates the development of choroidal neovascularization.

Authors:  Jinxian Xu; Xinglou Liu; Xinyan Zhang; Brendan Marshall; Zheng Dong; Yutao Liu; Diego G Espinosa-Heidmann; Ming Zhang
Journal:  J Pathol       Date:  2020-05-21       Impact factor: 7.996

10.  Neuroprotective effect of water-dispersible hesperetin in retinal ischemia reperfusion injury.

Authors:  Akito Shimouchi; Harumasa Yokota; Shinji Ono; Chiemi Matsumoto; Toshihiro Tamai; Hiroko Takumi; Subbadra P Narayanan; Shoji Kimura; Hiroya Kobayashi; Ruth B Caldwell; Taiji Nagaoka; Akitoshi Yoshida
Journal:  Jpn J Ophthalmol       Date:  2015-09-25       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.